From: 48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trial
TVD
AZT/3TC
p-value
% of Pts with HIV RNA < 50 c/mL (M = F)
92%
78%
0.12
Median CD4 count change (cell/mm3)
+60.5
+9
0.079